Cryo-Cell International, Inc. Common Stock (CCEL)
Healthcare › Services-Misc Health & Allied Services, NEC
Price History
Feb 9, 2026 — Aug 8, 2026Investment Snapshot
- P/E of 17.1 — reasonable valuation
- Piotroski F-Score 6/9 — moderate financial health
- Loss-making — negative ROE of -136.0%
- High dividend yield of 7.1%
Cryo-Cell International, Inc. Common Stock (CCEL) is a Healthcare company operating in Services-Misc Health & Allied Services, NEC, listed on the AMEX , with a market capitalisation of $29 million . Key value metrics: P/E ratio 17.1, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Revenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Cryo-Cell International, Inc. Common Stock — Fundamental Analysis Summary
Cryo-Cell International, Inc. Common Stock (CCEL) trades at a trailing P/E of 17.1x — 32% below the Healthcare sector average of 25.2x.
On financial health, CCEL shows a moderate Piotroski F-Score of 6/9, and negative return on equity of -136.0% (sector average: -20.1%).
StockPik's composite Value Score for CCEL is 52/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CCEL shows earnings declining at 704%.
CCEL pays a high dividend yield of 7.1%.